Welcome to our dedicated page for XWELL news (Ticker: XWEL), a resource for investors and traders seeking the latest updates and insights on XWELL stock.
XWELL, Inc. develops wellness and biosecurity services for travelers, commuters, and other people moving through high-traffic locations. Recurring updates cover XpresSpa airport spas, Naples Wax Center skincare and waxing locations, wellness retail openings, travel-product collaborations, and partnerships that expand access to services in airports and metropolitan areas.
Company news also covers XpresCheck biosecurity work, including traveler-based pathogen surveillance, nasal sampling, wastewater collection, and forecasting tools used with public health programs. Financial releases discuss revenue by brand, operating expenses, cost controls, capital actions, and corporate updates related to XWELL’s Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
XWELL, Inc. (Nasdaq: XWEL) announced its financial results for the year ending December 31, 2022, reporting total revenue of $55.9 million, a decrease from $73.7 million in 2021. The net loss attributable to common shareholders was $32.8 million, compared to a net income of $3.3 million the previous year. Key initiatives include the opening of new XpresSpa locations and partnerships to integrate innovative health technologies. The company’s operational adjustments led to a reduction in cash operating costs and the closure of underperforming locations. Financial metrics indicate a working capital of $36.4 million with no long-term debt. XWELL continues to focus on growth in wellness services at airports, expanding its biosurveillance program, and enhancing retail strategies.